Breaking Down Hims & Hers Health, Inc. (HIMS) Financial Health: Key Insights for Investors

Breaking Down Hims & Hers Health, Inc. (HIMS) Financial Health: Key Insights for Investors

US | Consumer Defensive | Household & Personal Products | NYSE

Hims & Hers Health, Inc. (HIMS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Hims & Hers Health, Inc. (HIMS) Revenue Streams

Revenue Analysis

According to the Q3 2023 financial report, the company reported $159.7 million in total revenue, representing a 4.3% year-over-year growth.

Revenue Stream Q3 2023 Revenue Percentage of Total Revenue
Telehealth Services $86.3 million 54.0%
Prescription Medications $45.2 million 28.3%
Consumer Products $28.2 million 17.7%

Key revenue insights for the fiscal year 2023 include:

  • Total annual revenue reached $638.5 million
  • Telehealth segment grew by 12.6% compared to previous year
  • Prescription medication revenue increased 7.8% year-over-year

Geographic revenue breakdown shows 92% of revenue generated within the United States market.

Region Revenue Contribution
United States $587.4 million
International Markets $51.1 million



A Deep Dive into Hims & Hers Health, Inc. (HIMS) Profitability

Profitability Metrics

Financial performance analysis reveals critical insights into the company's profitability landscape.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 76.5% 74.2%
Operating Profit Margin -15.3% -22.7%
Net Profit Margin -16.8% -25.4%

Key profitability observations include:

  • Revenue for 2023: $385.2 million
  • Gross profit: $294.8 million
  • Operating expenses: $230.5 million
Efficiency Metric 2023 Performance
Cost of Revenue $90.4 million
Sales & Marketing Expense $198.3 million
Research & Development $32.2 million



Debt vs. Equity: How Hims & Hers Health, Inc. (HIMS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital allocation strategy.

Debt Metric Amount ($ Millions)
Total Long-Term Debt $98.4 million
Short-Term Debt $22.6 million
Total Debt $121 million
Debt-to-Equity Ratio 1.45

Key debt financing characteristics include:

  • Credit Rating: B+ from Standard & Poor's
  • Interest Rates: Ranging between 6.5% - 8.2%
  • Debt Maturity Profile: Predominantly 3-5 year terms

Equity funding details demonstrate strategic capital management:

Equity Component Amount ($ Millions)
Total Shareholders' Equity $83.6 million
Common Stock Outstanding 187.3 million shares
Market Capitalization $1.2 billion

Recent financing activities highlight balanced capital strategy with 65% equity and 35% debt composition.




Assessing Hims & Hers Health, Inc. (HIMS) Liquidity

Liquidity and Solvency Analysis

As of Q4 2023, the company's financial liquidity metrics reveal critical insights for potential investors.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 1.23 2023
Quick Ratio 0.89 2023

Working Capital Trends

Working capital position for the fiscal year 2023 was $42.6 million, representing a 15.3% increase from the previous year.

Cash Flow Analysis

Cash Flow Category Amount Year
Operating Cash Flow $18.3 million 2023
Investing Cash Flow -$22.7 million 2023
Financing Cash Flow $12.5 million 2023

Liquidity Strengths

  • Positive operating cash flow of $18.3 million
  • Increased working capital by 15.3%
  • Current ratio above 1.0, indicating short-term solvency

Potential Liquidity Concerns

  • Quick ratio below 1.0 at 0.89
  • Negative investing cash flow of $22.7 million



Is Hims & Hers Health, Inc. (HIMS) Overvalued or Undervalued?

Valuation Analysis: Is the Company Overvalued or Undervalued?

As of February 2024, the company's financial valuation metrics reveal critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Book (P/B) Ratio 3.68
Enterprise Value/EBITDA -11.23
Current Stock Price $4.87

Stock price performance analysis for the past 12 months demonstrates significant volatility:

  • 52-week low: $2.65
  • 52-week high: $7.39
  • Total stock price decline: 34.2%

Analyst recommendations provide additional perspective:

Recommendation Percentage
Buy 45%
Hold 35%
Sell 20%

Dividend metrics indicate no current dividend distribution.




Key Risks Facing Hims & Hers Health, Inc. (HIMS)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Competitive Landscape Risks

Risk Category Potential Impact Current Market Position
Digital Health Competition Market share erosion $500 million total addressable market
Telehealth Services Pricing pressure 15% market penetration

Regulatory and Compliance Risks

  • FDA regulatory compliance challenges
  • Potential changes in telehealth reimbursement policies
  • State-level licensing restrictions

Financial Risk Indicators

Financial Metric 2023 Value Risk Level
Cash Burn Rate $42 million per quarter High
Debt-to-Equity Ratio 1.2 Moderate

Operational Risks

  • Technology infrastructure vulnerabilities
  • Patient data privacy concerns
  • Supply chain disruptions for prescription medications

Key external risks include 36% potential market volatility and increasing healthcare technology competition.




Future Growth Prospects for Hims & Hers Health, Inc. (HIMS)

Growth Opportunities

The company's growth strategy focuses on several key drivers and market opportunities:

  • Total addressable market for telehealth estimated at $250 billion by 2025
  • Digital health market projected to reach $639.4 billion globally by 2026
  • Telemental health services expected to grow at 23.7% CAGR through 2028
Growth Metric 2023 Value 2024 Projection
Revenue Growth $385.9 million $455-$475 million
Customer Acquisition 1.6 million active subscribers 1.9-2.1 million projected
Product Line Expansion 7 therapeutic categories 9-10 planned categories

Strategic expansion initiatives include:

  • International market penetration in Canada and potential European markets
  • Continued investment in $15 million annual R&D
  • Potential strategic acquisitions in complementary digital health sectors

Key competitive advantages:

  • Proprietary technology platform
  • Direct-to-consumer digital health model
  • Scalable technology infrastructure

DCF model

Hims & Hers Health, Inc. (HIMS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.